To date, there are no published clinical studies using CAR in ACT therapy for melanoma; nevertheless, in vitro studies utilizing chimeric receptor against melanoma antigens such as ganglioside GD2, GD3, and MAGE-A1 were reported [69–71]. This evidence concerns the gene MAGEA1 and melanoma.